Wei Wang, MD, PhD, and colleagues conducted the study and published its findings in Cancers. The combination led to an overall survival rate of nearly 75% in patients with BPDCN... First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid... Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients. Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.